// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Dilute Thrombin Time versus activated Partial thromboplastin Time to monitor Argatroban in critically ill patients.

S. Cox-Morton - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Argatroban

Direct Oral Anti-Coagulant (DOAC) external quality assessment (EQA) scheme assay results and interpretations from UKNEQAS BC DOAC Survey 19 2021.

C. Reilly-Stitt - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Direct oral anticoagulant prescribing in patients with a very low bodyweight – experience from King’s College Hospital

R. Clapham - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Direct Oral Anticoagulants compared with Warfarin for the Treatment of Left Ventricular Thrombosis post Myocardial Infarction

R. Byrne - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

Warfarin

Direct oral anticoagulants in the management of cerebral sinus vein thrombosis: A single centre experience

U. Faruqi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Discrepant results for ADAMTS13 assays with different activity assays. Artefact or cause for concern?

I. Jennings - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Disease Relapse in immune Thrombotic Thrombocytopenic Purpura and treatment with Anti-CD20 Monoclonal Antibodies – 10-years’ experience from the UK TTP Registry

A. Doyle - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombotic thrombocytopenic purpura

Rituximab

Disruption of the interaction of platelets with leukocytes by a novel short synthetic peptide targeting P-selectin

S. Wallis - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Dynamic changes in activated protein C during major haemorrhage protocol and associated fibrinolytic response

A. Thaventhiran - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Trauma

Protein C

Effect of anti -factor Xa direct oral anticoagulants (DOACs) on viscoelasticity measurements in External Quality Assessment (EQA) samples: UK NEQAS BC experience

D. Kitchen - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Heparin

Effects of platelet-inspired haemostatic nanoparticles on bleeding in von Willebrand disease murine models

S. Roullet - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Efficacy and safety of prothrombin complex concentrate for major bleeding in patients treated with direct Factor-Xa inhibitors

R. Clapham - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Prothrombin complex

Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study

A. von Drygalski - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases

V. McDonald - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Intratect

Elucidation of Specific Platelet Signaling Pathways Perturbed in SLFN14-Mutated Patients with Inherited Macrothrombocytopenia and Bleeding

R. Stapley - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Macrothrombocytopenia

N/A

Emicizumab Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study

C. Hermans - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Emicizumab prophylaxis in people with severe haemophilia A without inhibitors: outcomes from the UK Haemophilia Centre Doctors’ Organisation

C. Wall - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Endothelial-induced regulation of platelet signalling under flow: establishing the endothelial-controlled platelet phosphoproteome

I. Provenzale - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Eptacog beta for resolution of bleeding episodes in patients with hemophilia A or B with inhibitors: Efficacy and safety according to inhibitor titer

D. Hart - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Evaluating routine data sources and efficient methods to determine the incidence of venous thromboembolism and major bleeding in unselected medical and surgical inpatients.

D. Horner - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Copyright © 2026. QuantiNova All rights reserved